KLOW is a four-peptide research blend that brings GHK-Cu, BPC-157, TB-500 and KPV together in a single 80 mg vial — a combination studied across the tissue-repair, skin and recovery literature. This page covers what is in the blend, the research areas each component appears in, and how to source it with documentation from Australian stock.
What is KLOW?
KLOW is a combination (blend) research peptide — a single vial that holds four separately studied compounds rather than one. Each of the four is a well-characterised research peptide in its own right, and each has its own dedicated page in our library; KLOW simply provides them together in fixed proportions in one lyophilised vial. It is supplied strictly for laboratory and in-vitro research use.
The four sit together for a reason: they are the compounds most frequently studied side by side in the tissue-repair and recovery literature. Rather than reconstituting four vials, a researcher working in that area has the set in one.
What is in the KLOW blend
Each 80 mg vial contains, in approximate amounts:
- GHK-Cu (~50 mg) — a copper-binding tripeptide (glycyl-L-histidyl-L-lysine). Studied in skin-regeneration, collagen-synthesis and tissue-remodelling research.
- BPC-157 (~10 mg) — "Body Protection Compound 157", a synthetic peptide fragment. Studied in gut-lining support, tendon-healing and tissue-repair research.
- TB-500 (~10 mg) — a Thymosin Beta-4 fragment. Studied in cell-migration, joint-mobility and muscle-recovery research.
- KPV (~10 mg) — the lysine-proline-valine tripeptide (a C-terminal fragment of α-MSH). Studied for its anti-inflammatory and immune-modulating properties.
These describe fields of scientific study — they are not claims about effects in humans. Nothing here should be read as a statement about what the blend does in a person; NextGen Peptides supplies KLOW strictly for laboratory and in-vitro research use.
Research areas
Because KLOW combines four compounds, its research context is the overlap of theirs — most of it sitting in the broad tissue-repair and recovery field. GHK-Cu anchors the skin, collagen and extracellular-matrix strand; BPC-157 and TB-500 are the two compounds most often studied together in recovery and connective-tissue research; and KPV adds the anti-inflammatory and immune-signalling angle. Studied together, they are of interest to researchers examining recovery and repair processes from several directions at once.
Storage & handling
Supplied as a lyophilised (freeze-dried) powder. Because of the GHK-Cu content it carries a blue tint once mixed (from the bound copper). Store at −20°C; refrigerate at 2–8°C after mixing and keep out of light. See our full guide to storing and reconstituting research peptides, what to mix it with in our bacteriostatic water guide, and work out concentration with the reconstitution calculator. Run diluent slowly down the vial wall and swirl rather than shake; never refreeze a reconstituted solution.
Sourcing KLOW in Australia
We hold KLOW in Australian stock, so orders placed before the daily cut-off are dispatched same or next business day — no overseas freight, no customs wait. Every batch is independently third-party tested, with the Certificate of Analysis published. New to buying research peptides? Read our Australian buyer's guide and the full Peptides Australia guide first.
Common questions about KLOW
What is KLOW?
A combination (blend) research peptide — a single 80 mg vial containing four separately studied compounds: GHK-Cu, BPC-157, TB-500 and KPV. Supplied for laboratory research use only.
What is in the KLOW blend?
GHK-Cu (~50 mg), BPC-157 (~10 mg), TB-500 / Thymosin Beta-4 fragment (~10 mg) and KPV (~10 mg). Each is covered in depth on its own research page.
Why is KLOW blue when reconstituted?
The blue tint comes from the copper bound to the GHK-Cu component, not from any additive — a clear blue solution is expected. Cloudiness or loss of colour is a visual signal worth noting.
Is KLOW tested and does it come with a CoA?
Yes. Every batch is independently tested for purity and identity, with the Certificate of Analysis published.
Is KLOW held in Australian stock?
Yes. We hold KLOW in Australian stock and dispatch same or next business day for orders placed before the daily cut-off.
Legal status and intended use
KLOW is supplied by NextGen Peptides strictly as a research chemical for laboratory and in-vitro use. It is not an approved therapeutic good in Australia, it is not supplied for human or veterinary consumption, and nothing on this site constitutes medical advice. Purchasers must be 18 or over. For the regulatory framework, see our guide to the legal status of research peptides in Australia.
Quick facts
SKU: KLOW-80 · 80MG per vial (GHK-Cu ~50 · BPC-157 ~10 · TB-500 ~10 · KPV ~10) · Batch-tested with published CoA · Held in Australian stock · Same or next business day dispatch · For laboratory research use only.
Related research
Explore the four compounds inside KLOW, each held in Australian stock: GHK-Cu, BPC-157, TB-500 and KPV. Prefer a skin-only blend? See GHK-Cu and the GLOW Blend in the shop.
Part of our complete guide to research peptides in Australia.
Supplied strictly for laboratory and in-vitro research use only. Not for human or veterinary consumption. The research areas listed describe fields of scientific study, not claims about effects in humans, and nothing here is medical advice.